Abiraterone Acetate

• ATA-200 gene therapy trial in patients with LGMDR5 Pending
  2023-506440-16-00 Phase I (FiH) 2 countries Atamyo Therapeutics
• Comparison of standard abiraterone dosing and dosing based on abiraterone blood levels Pending
  2025-524440-35-00 Phase IV 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 Phase III 11 countries AstraZeneca AB
• A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t… Recruiting
  2022-500461-28-06 Phase III 12 countries Eli Lilly & Co.; Eli Lilly Cork Limited
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 Phase III 15 countries Merck Sharp & Dohme LLC
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting
  2024-517653-27-00 Phase II 5 countries Astellas Pharma Global Development Inc.
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting
  2024-513586-39-00 Phase III 11 countries AstraZeneca AB
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 Phase III 9 countries Amgen Inc.
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting
  2022-502408-57-00 Phase III 6 countries Unicancer
• Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c… Recruiting
  2023-505024-62-01 Phase II 1 country Instituto de investigación en Oncología radioterápica FEOR (Fundación Española …
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting
  2023-504899-25-00 Phase III 14 countries Merck Sharp & Dohme LLC
• A Randomised study comparing Lutetium-177 versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer in PSM… Recruiting
  2022-500570-33-00 Phase III 1 country Region Västerbotten; Umea University
• Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting
  2022-502254-13-00 Phase III 1 country UZ Leuven
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 Phase III 3 countries Karolinska Institutet
• Gene Therapy for Crigler-Najjar Syndrome Recruiting
  2023-507007-60-00 Phase I (FiH) 3 countries Genethon
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended
  2024-513968-25-00 Phase III 11 countries Amgen Inc.
• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn… Ended
  2023-505394-32-00 Phase III 13 countries Sanofi-Aventis Research & Development
• A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie… Ended
  2022-501493-19-00 Phase III 3 countries Curium Pet France
• ATA-100 gene therapy trial in patients with limb-girdle muscular dystrophy Ended
  2023-506677-36-00 Phase I (FiH) 2 countries Atamyo Therapeutics
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Ended
  2023-508536-64-00 Phase I/II 1 country AstraZeneca AB
• An International, Randomized, Double-Blind, Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Pl… Ended
  2023-509396-16-00 Phase III 6 countries Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap… Ended
  2023-507772-50-00 Phase III 9 countries Novartis Pharma AG
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-506365-64-00 Phase III 13 countries Janssen - Cilag International
• Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio… Ended
  2024-516481-11-00 Phase III 9 countries Exelixis Inc.

Showing 1–24 of 32 trials